目的：探讨Ki-67表达在乳腺癌新辅助化疗中价值。方法收集82例接受新辅助化疗的乳腺癌患者作为研究对象，采用免疫组化法检测患者新辅助化疗前后Ki-67表达情况，比较分析穿刺前Ki-67表达情况与化疗疗效的相关性。结果新辅助化疗后Ki-67表达率显著下降，与化疗前比较，差异具有统计学意义（P＜0.05）；化疗前Ki-67低表达者有效率显著高于化疗前Ki-67高表达者，差异具有统计学意义（P＜0.05）。结论Ki-67表达情况可作为乳腺癌严重程度判断、化疗方案选择以及预测化疗效果的可靠依据。

Objective To explore the expression of Ki-67 after neoadjuvant chemotherapy in breast cancer. Methods 82 cases of patients with breast cancer after neoadjuvant chemotherapy were researched.The expression of Ki-67 were tested by immunohistochemical.The correlation between expression of Ki-67 and chemotherapeutic effect were compared. Results The expression percentage of Ki-67 posttreatment were lower than prior-treatment (P < 0.05);The effective rate with low expression for Ki-67 negative was higher than high expression for Ki-67 positive(P<0.05). Conclusion The expression of Ki-67 after neoadjuvant chemotherapy in breast cancer is reliable basis for order of severity,chemotherapy regimens and curative effect of chemotherapy.

目的探讨CD105和Ki67蛋白在卵巢上皮癌(EOC)中的联合表达及与其临床病理特征及预后的关系。方法采用免疫组化方法检测166例卵巢上皮癌患者石蜡包埋标本中CD105和Ki67蛋白表达。结果 CD105阳性表达率为75.9%(126/166),Ki67阳性表达率为66.3%(110/166),CD105、Ki67共同表达率为51.8%(86/166)。CD105和Ki-67在EOC中的表达呈正相关(γ=0.66,P=0.01),两者的表达与EOC淋巴结转移、临床分期呈正相关性,但与其组织细胞学分化程度及患者总体生存率呈负相关性。CD105和Ki67表达与患者总生存率显著相关。结论 CD105和Ki67蛋白表达参与卵巢上皮癌的发生、发展;CD105和Ki67均为ECO预后不良的指标。

Objective To investigate the correlation of expression of CD 105 and Ki67 and the clinical pathological fea-tures and prognosis in epithelia ovarian cancer (EOC).Methods Expression of CD105 and Ki67 in 166 paraffin embedding specimens of EOC were detected by immunohistochemistry method .Results The positive expression rates of CD 105 and Ki67 in EOC were 75.9% (126/166) and 66.3% (110/166),respectively.The co-expression rate of CD105 and Ki67 was 86/166 (51.8%).The expression of CD105 was positively correlated with Ki67(γ=0.66,P=0.01).The expression of CD105 and Ki67 were positive correlated with lymph node metastasis and clinical staging .But they were negative related with differentiation and patient ’ s overall survival .Conclusion CD105 and Ki67 protein interaction may be involved in the occurrence ,development and prognosis of EOC;CD105 and Ki67 are prognostic predictors .

目的观察不同分子亚型乳腺癌中Ki-67的表达及其与乳腺癌临床病理特征的关系及意义。方法采用免疫组化EnVision两步法检测245例乳腺癌组织中ER、PR、HER-2及Ki-67的表达,并比较Ki-67表达与乳腺癌临床病理参数的关系。结果不同分子分型乳腺癌中Ki-67的增殖指数差异有统计学意义（P〈0.05）;有淋巴结转移及肿块较大者中Ki-67增殖指数高于无淋巴结转移及肿块较小者,ER、PR阳性者中Ki-67增殖指数低于ER、PR阴性者,差异有统计学意义;患者按中位年龄50岁进行分组时,≤50岁组与〉50岁组的Ki-67增殖指数差异无统计学意义;患者按≤40岁及≥60岁分为年轻组及老年组时,年轻组Ki-67增殖指数明显高于老年组。结论 Ki-67在三阴型乳腺癌、年轻患者、伴腋窝淋巴结转移、肿块较大及ER、PR阴性组中的增殖指数较高。Ki-67可作为判断乳腺癌预后的重要指标。

Purpose To study the expression of Ki-67 in breast cancer with different molecular classification, and to discuss the rela-tionship between the expression of Ki-67 and clinical pathological features in breast cancer. Methods All 245 patients with breast cancer were divided into different molecular classification through detecting the expression of ER, PR, HER-2 by immunohistochemical method. The expression of Ki-67 was also detected, and to study relationship between the expression and clinical pathological features. Results The difference of Ki-67 index was statistically significant in different molecular classification of breast cancer. Ki-67 index in patients with lymph node metastasis and larger tumor size were higher than that with no metastasis and smaller tumor size. Ki-67 index in patients with ER and PR positive were lower than that negative, the difference was statistically significant. Ki-67 expression differ-ence was not statistically significant between the two g

目的研究Ki-67、DNA拓扑异构酶Ⅱα(TopoⅡα)在壶腹癌中的表达,探讨其与壶腹癌病理及生存状况的关系。方法应用SP免疫组化技术,检测71例壶腹癌Ki-67、TopoⅡα的表达,并对其与壶腹癌病理及预后的关系进行分析。结果 Ki-67、TopoⅡα的阳性表达率分别为71.8%(51/71),45.1%(32/71);Ki-67、TopoⅡα的表达以及两者的共表达均与肿瘤直径有关(P=0.008,P=0.029,P=0.004)。Ki-67与TopoⅡα的表达呈显著正相关(r=0.378,P=0.001)。Ki-67、TopoⅡα阴性表达者的术后生存率明显优于阳性表达者(P=0.018,P=0.001)。Ki-67与TopoⅡα共阳性表达者的生存率明显低于共阴性表达或单阴性表达者(P=0.001,P=0.018)。结论 Ki-67、TopoⅡα可作为判断壶腹癌患者预后的参考指标,联合检测二者的表达水平对壶腹癌的预后判断有一定的参考意义。

Objective To examine the expression of Ki-67 and topoisomeraseⅡα( TopoⅡα) in ampullary carcinoma, and investigate the correlation of Ki-67, TopoⅡα with pathological data and prognosis. Methods The SP immunohistochemical method was used to examine the expression of Ki-67, TopoⅡα in 71 ampullary carcinomas. The correlation of the two factors with pathological data and prognosis was analyzed statistically. Results The positive rate of Ki-67 and TopoⅡα expression was 71.8%(51/71), 45.1%(31/71), respectively. The expression of Ki-67, TopoⅡαand their coexpression were associated with tumor diameter (P=0.008, P=0.029, P=0.004). Ki-67 expression was significantly correlated with TopoⅡαexpression (r=0.378, P=0.001).The expression of Ki-67, TopoⅡαhad significant negative correlation with survival period (P=0.018, P=0.001). The survival period of patients with coexpression of Ki-67 and TopoⅡα was obviously lower than those without Ki-67 and/or TopoⅡαexpression (P=0.0

目的 探讨细胞核增殖抗原(Ki-67)在肾细胞癌组织中表达的临床意义.方法 应用免疫组织化学方法检测Ki-67在70例肾细胞癌组织及30例正常肾脏组织中的表达.结果 肾细胞癌组织中Ki-67表达阳性率为64.29％-Ki-67表达与肾细胞癌分级、分期明显相关(P＜0.05),与肾癌的病理类型无明显相关(P＞0.05).结论 检测Ki-67有助于反映肾细胞癌生物学行为.

Objective To explore the clinical significance of proliferation cell nuclear antigen (Ki-67) expression in renal cell carcinoma (RCC).Methods The immunohistochemistry staining method was used to evaluate the expression of Ki-67 in 70 cases of RCC and 30 cases of normal renal tissue as controls.Results The positive expression rate of Ki-67 was 64.29％ in RCC.The positive expression rate of Ki-67 in RCC was significantly related to the clinical stage or clinical grade (P ＜ 0.05),but not to the types of RCC (P ＞0.05).Conclusion Ki-67 is an objective marker to estimate the behaviors of RCC.